Kadmus Pharmaceuticals raised a round of funding on February 20, 2004.
Kadmus has developed products for a variety of conditions through the inhibition of endocannabinoid degradation (FAAH inhibitors), activation of endocannabinoid related pathways (OEA), and activation …
